• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
ProAxsis gains CE Mark for Active Neutrophil Elastase Immunoassay
Share
Neutrophil Elastase Immunoassay, News, ProteaseTag®

ProAxsis gains CE Mark for Active Neutrophil Elastase Immunoassay

September 30, 2016
-
Posted by Webmaster

ProAxsis Limited (www.proaxsis.com) is pleased to announce that it has successfully registered a CE Mark for its novel ProteaseTag® Active Neutrophil Elastase Immunoassay.  Neutrophil elastase is a well-recognised biomarker of lung inflammation and infection in chronic respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD), cystic fibrosis and bronchiectasis.  The registration of a CE Mark indicates that the ProteaseTag® Active Neutrophil Elastase Immunoassay complies with EU legislation, and enables the company to commercialise the Immunoassay throughout the European market.

Commenting on the news, Dr David Ribeiro, CEO of ProAxsis, said: “This is a very proud day for everyone at ProAxsis, with the successful registration of our first CE Mark.  We have already had enquiries from a number of pharmaceutical companies concerning the commercial use of our ProteaseTag® Active Neutrophil Elastase Immunoassay in their upcoming clinical trials, and look forward to making the assay more widely available to the respiratory community now that it has its CE Mark.  I would particularly like to acknowledge the work of Dr Charlene Robb, who has led the regulatory efforts that have enabled us to reach this significant milestone.”

Any queries concerning ProAxsis’ Immunoassay for measuring active neutrophil elastase, or any requests for support with measuring other active protease biomarkers using the Company’s proprietary ProteaseTag® technology, can be directed to info@77.104.171.207.

September 30, 2016

Related News

Other posts that you should not miss.
News

ProAxsis featured in Business Eye

September 16, 2016
-
Posted by Webmaster

ProAxsis (www.proaxsis.com) is delighted to have been featured in the latest edition of Business Eye, Northern Ireland’s premium …

Read More
September 16, 2016
Posted by Webmaster
Announcements, News, ProteaseTag®

ProAxsis successfully licenses additional intellectual property from The Queen’s University of Belfast

May 10, 2017
-
Posted by Webmaster

ProAxsis Limited (www.proaxsis.com) is delighted to announce that it has secured a second licensing agreement with the Queen’s …

Read More
May 10, 2017
Posted by Webmaster
News, ProteaseTag®

ProAxsis gains further support from Innovate UK

July 24, 2017
-
Posted by Webmaster

Following its previous success in the BioMedical Catalyst competition, ProAxsis Limited (www.proaxsis.com) has now gained further support for …

Read More
July 24, 2017
Posted by Webmaster
← PREVIOUS POST
ProAxsis receives Royal visit
NEXT POST →
ProAxsis CEO to present at Biotech in Europe
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis Limited appoints first distributor for DACH region
    December 14, 2020

    ProAxsis Limited (www.proaxsis.com), the Belfast-based diagnostics company specialising in the measurement of active …

  • ProAxsis Limited supported by Innovate UK to accelerate work on inflammatory biomarkers associated with COVID-19
    December 10, 2020

    ProAxsis (www.proaxsis.com), the Belfast-based respiratory diagnostics company, today announces that it has been …

  • ProAxsis Limited recognised as Gold Level Innovator by Innovate NI
    December 2, 2020

    ProAxsis (www.proaxsis.com), the Belfast-based protease diagnostics company, is delighted to announce that it …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • February 21, 2021
    ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
  • December 14, 2020
    ProAxsis Limited appoints first distributor for DACH region
  • December 10, 2020
    ProAxsis Limited supported by Innovate UK to accelerate work on inflammatory biomarkers associated with COVID-19
LATEST TWEETS
Twitter
ProAxsis
Follow Me
ProAxsis is delighted to have received this support from Innovate UK - https://t.co/toTxOz9KK6
124 days ago
- ProAxsis
RT @GRobinsonDUP: I’m delighted that @ProAxsis based in East Belfast have been successful in their application for an Innovate UK Grant, wh…
124 days ago
- ProAxsis
We are delighted to announce that as of today, we have appointed an exclusive distributor for our portfolio of prod… https://t.co/rmCmIugsLa
145 days ago
- ProAxsis
Due to our continued expansion, we wish to recruit an Administration Officer. This post can be full-time or part-ti… https://t.co/k3wKwVfOKy
165 days ago
- ProAxsis
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
ProAxsis gains CE Mark for Active Neutrophil Elastase Immunoassay | ProAxsis